Please complete this activity then scroll to the end and click 'Done'
Thank you for completing this CPD activity. Please complete this evaluation, we will then provide you with a certificate so that you can claim CPD credits.

Question Title

* 1. First Name

Question Title

* 2. Last Name

Question Title

* 3. Contact Email

Question Title

* 4. Contact telephone

Question Title

* 5. Please rate to what degree your learning needs were met:

Question Title

* 6. Please rate how well the following learning outcome was met: Recognise the range of patients and clinical presentations for CV disease, including the impact of associated comorbidities, and tailor management strategies accordingly.

Question Title

* 7. Please rate how well the following learning outcome was met: Apply coordinated treatment for TIA according to the latest guidelines.

Question Title

* 8. Please rate how well the following learning outcome was met: Identify and assess CV disease, know when to treat and when to refer for specialist care or to the ED.

Question Title

* 9. Please rate how well the following learning outcome was met: Effectively manage the more complex patients with CV disease, including those returning to your care following specialist care or hospital treatment.

Question Title

* 10. Please rate to what degree this activity is relevant to your practice

Question Title

* 11. Has this activity contributed to a systems-based patient safety outcome for your practice?

Question Title

* 12. How useful has this meeting been in providing solutions to the current treatment challenges faced by GPs?

Question Title

* 13. As a result of the education you have received, do you have increased confidence in managing AF/VTE and related CV disease?

Question Title

* 14. Would you recommend this education to a colleague?

Please click 'Done' below to submit your questionnaire
The TGA encourages health professionals to report adverse events to medicines and vaccines. Suspected adverse events reported by health professionals provide important information for the TGA’s safety monitoring program. For further details on reporting a suspected adverse event, please refer to the TGA website: www.tga.gov.au. If you report an adverse event associated with the use of ELIQUIS to the TGA, please provide Pfizer or BMS with a copy.

Question Title

Image

T